Clinical Trial

Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-03-25; most recent amendment 2025-10-20.
Status change: Not Yet Recruiting → Recruiting 2020-08-12
Trial Details
NCT Number NCT04323735
Lead Sponsor Medstar Health Research Institute
Collaborators: Children's National Research Institute
Conditions Neurogenic Bladder
Enrollment 182 participants
Start Date 2020-01-10
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-10-22